U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07604233) titled 'Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML' on May 18.
Brief Summary: The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Study Start Date: Nov. 30, 2026
Study Type: INTERVENTIONAL
Condition:
Myeloid Leukemia
Intervention:
DRUG: Fludarabine
Given by IV
DRUG: Cytarabine
Given by IV
DRUG: Idarubicin
Given by IV
DRUG: Filgrastim
Given by injection
DRUG: Venetoclax
Given by orally
DRUG: As...